US FDA Advises Manufacturers To Test For Nitrosamines In All APIs, Drug Products

Guidance is FDA's latest action in response to findings that over time in storage, especially at higher temperatures, levels of the probable carcinogen NDMAincreases in some ingredients, including ranitidine available in OTC heartburn remedies.

chemistry

The US Food and Drug Administration is advising drug manufacturers to assess the nitrosamine impurity risks associated with all chemically synthesized active pharmaceutical ingredients and all approved or marketed drug products that contain those APIs before March 2021.

They should follow up with confirmatory testing and submission of any required changes in their drug applications, starting immediately for...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Regulation

More from Policy & Regulation